Abstract 1500
Background
Docetaxel (Doc) was initially licenced for CRPC (TAX327) but more recently trials showed Doc at HSPC diagnosis improved survival, shifting patterns of use. Higher neutropenic toxicity rates were reported in the HSPC trials, but it is unclear if this was due to the Doc timing or differences in case-mix. We compared sepsis rates for Doc at HSPC and CRPC using routine NHS data for men randomised in STAMPEDE in England.
Methods
STAMPEDE patient data were linked to routine NHS data (Hospital Episode Statistics: HES; Systemic Anti-Cancer Therapy: SACT). Patient note review (ref) linked to NHS data assessed admission rates by HSPC & CRPC Doc at 1 site (N = 44) and were used to develop and validate algorithms for detecting sepsis events across the entire data set. Algorithms were restricted to sepsis-only & sepsis + neutropenia (S+N) (N = 3645). Missing HES CRPC Doc regimens were imputed with HES (N = 3645) or enhanced with SACT (N = 1573). Odds ratios (OR) were calculated for risk of sepsis (OR < 1 = lower risk for HSPC).
Results
Sepsis rates varied by method; for most, rates at CRPC were higher than in TAX327 but similar to or higher than reported STAMPEDE HSPC data.Table:
862P
HSPC Sepsis/Pts | CRPC Sepsis/Pts | % diff | OR, 95% CI | |||
---|---|---|---|---|---|---|
N | % | N | % | |||
Ref | ||||||
2/15 | 13 | 6/22 | 27 | -14 | 0.4 (0.1 - 2.1) | |
HES | ||||||
Sepsis | 69/834 | 8 | 114/1183 | 10 | -2 | 0.9 (0.6 - 1.2) |
S+N | 134/834 | 16 | 148/1183 | 13 | 3 | 1.3 (1.0 - 1.6) |
Imputed | 134/834 | 16 | 489/1351 | 36 | -20 | 0.4 (0.4 - 0.6) |
+ SACT | 41/200 | 21 | 60/297 | 20 | 1 | 1.0 (0.7 - 1.6) |
Conclusions
This analysis does not support the hypothesis that HSPC Doc has a higher sepsis risk than Doc use in CRPC. Sepsis rates found using routine data were higher than in the TAX327 trial but similar to reported “real world” CRPC data. Rates varied by data-identification method used; for most, CRPC sepsis rates were higher or similar to HSPC rates & overall a little higher than the reported STAMPEDE HSPC rate. These data suggest CRPC Doc has a similar or higher sepsis rate than use in HSPC & this should be factored into discussions for men with newly-diagnosed metastatic HSPC and supports Doc use in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The STAMPEDE Trial Group.
Funding
University of Warwick, Warwick Medical School (HM PhD studentship).
Disclosure
M.K.B. Parmar: Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Clovis oncology; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution), The Unit I am Director of also receives educational grants and other non- financial support from a large number of different companies: Other. P. Patel: Advisory / Consultancy: Roche/Genentech. M.R. Sydes: Honoraria (self): Lilly; Honoraria (self), Research grant / Funding (self): Sanofi; Honoraria (self): Janssen; Research grant / Funding (self): Astellas Pharma; Research grant / Funding (self): Janssen-Cilag; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Novartis; Research grant / Funding (self): Clovis Oncology. N.D. James: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen; Honoraria (self), Speaker Bureau / Expert testimony: Pierre Fabre; Speaker Bureau / Expert testimony: Ferring; Honoraria (self): Oncogenex; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract